BONE SUBSTITUTES OUTCOMES - Trial NCT06374342
Access comprehensive clinical trial information for NCT06374342 through Pure Global AI's free database. This phase not specified trial is sponsored by Teknimed and is currently Recruiting. The study focuses on Bone Resorption. Target enrollment is 425 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Teknimed
Timeline & Enrollment
N/A
Sep 16, 2021
Sep 30, 2032
Primary Outcome
Successful bone repair
Summary
A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and
 performance of all TEKNIMED Bone Substitute range of products: CERAFORM, TRIHA+, NANOGEL, and
 all their private labels.
 
 TEKNIMED bone substitutes are legacy products, some marketed for more than 20 years. Their
 performance and safety have already been demonstrated by Post-Market Surveillance and
 previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm
 these claims by collecting data in a real-life setting.
 
 The study is a retrospective and prospective global, single arm, non-controlled,
 multicentric, prospective observational study. Patients will be followed as per local
 standard medical care of the sites.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06374342
Device Trial